University of Wisconsin Newborn Screening for SCID Experience: Spanning the Spectrum Christine Seroogy MD Associate Professor Pediatric Allergy, Immunology.

Slides:



Advertisements
Similar presentations
DSHS Texas Newborn Screening Program Processes Susan Tanksley, PhD David Martinez April 10, 2008.
Advertisements

SCID Review Discussion. Decision Matrix Key Questions 1.This is the overarching question for the evidence review: Is there direct evidence that screening.
Neonatal Hematology for the Primary Care Physician Vlad C. Radulescu, M.D. University of Kentucky.
Newborn Screening for SCID and Other PIDs INGID 2012.
NBS for SCID: State Status NBSTRN Update Michael Watson.
DR. PETER VICKERS UNIVERSAL NEWBORN SCREENING FOR SCID.
Stem Cells: Roadmap to the clinic Negar Azarpira, MD Associate professor of Pathology 14 April 2010.
Final Case Study: Case #3 Rabin Anouseyan Alex Huynh Kimberly Rampasan California State University, Los Angeles Department of Biological Sciences.
AMCHP 2005 Conference Newborn Screening in Maryland The Maryland Program Informed Consent Informational Materials Linkage to Services Challenges of Working.
Severe combined immune deficiency in Nablus Omar Abuzaitoun, MD.
Confirmatory Testing Considerations
Perinatal Hepatitis B Prevention
Successful allogeneic SCT in infant with FHL, dilemmas in using „unaffected“ sibling P.Sedláček, R. Špíšek, et al 2nd Medical School, Charles University,
Nomination and Prioritization Reports: MPS I and Pompe Disease Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of.
Molecular LDT in Newborn Screening Laboratories
Francis K. Lee, M.Sc, Ph.D. Senior Service Fellow (Research Microbiologist) Newborn Screening Translation Research Initiative, CDC Emeritus Professor of.
Michigan Birth Defects Registry Overview and Status.
SUDHA KOLLA. HISTORY “Bubbly boy disease” “Bubbly boy disease” Known and discovered in 1970’s and 80’s Known and discovered in 1970’s and 80’s David Vetter.
Engineered Cells and Tissues Locksley McGann, PhD Professor Department of Laboratory Medicine and Pathology University of Alberta 24 April, 2012 Analytics,
In Vitro Fertilization and Preimplantation Genetic Diagnosis
Diagnosis of Primary Immunodeficiency
Decision Support for Quality Improvement
Increasing Access to Hearing Screening for Out of Hospital Births.
Call in number: Conference code: NBSTRN SCID National Call February 24, 2012.
FATIMA DARAKHSHAN (2K10-BS-V&I-35)
Tolerance Induction after Kidney Transplantation Stephan Busque MD M Sc FRCSC Director, Adult Kidney and Pancreas Transplantation Program Stanford University.
Gene Therapy Trials for PID:A Nursing Perspective Jin Hua Xu-Bayford Clinical Nurse Specialist Gene Therapy The child first and.
Diagnosis and treatment of ADA deficiency - first patient diagnosed in Czech Republic R. Formánková, P. Sedláček, O. Hrušák, J. Zeman, K. Dlask, E. Mejstříková,
Severe Combined Immunodeficiency Syndrome A heterogeneous group of congenital disorders which results in the absence of antigen-specific T and B cell responses.
BY : Dr. Amer Mahmood Dalia Ali. Introducing….stem cells!
Newborn Screening for Severe Combined Immune Deficiency: Advocacy, Challenges, and Next Steps Marcia Boyle President and Founder Immune Deficiency Foundation.
Recommendation to ACHDNC for Newborn Screening for X-linked Adrenoleukodystrophy Fred Lorey, Ph.D. Don Bailey, Ph.D. Liaisons to the Condition Review Workgroup.
Migle Janeliuniene, MD, PhD Lithuania Teaching/research/clinical Associate, Specialist Vilnius University Hospital Santariskiu Klinikos Santariskiu 2 LT
Provider initiated testing in Kenya Ruth Nduati Associate Prof Paediatrics University of Nairobi.
P-CID patient discussion form. Patient summary y/o boy/girl with: – Infection – Immune dysregulation – T cell deficiency Consanguinity: Family history:
Successful sequential cord blood stem cell transplant and intestinal-colon transplant for combined immunodeficiency and intestinal failure.
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) I.Tezcan, T.Turul, D. Uckan, M.Cetin, O.Sanal,
Adenosine-Deaminase (ADA) Deficiency ADA is responsible gene in ~20% SCID. Often fatal, if untreated, due to infections. It was the first form of SCID.
A classic case of loosing options… Hans H Hirsch Transplantation & Clinical Virology Department Biomedicine (Haus Petersplatz) Division Infection Diagnostics.
Follow-up of a patient with CERNUNNOS deficiency Edyta Heropolitańska-Pliszka Immunology Department Children’s Memorial Health Institute Warsaw, Poland.
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
TREC SCREENING. Characteristics of Disorders Characteristics of Test Well characterized pathogenesis Affects a significant number of infants Undetectable.
PRACTICE TEACHING ON THALASSEMIA. INTRODUCTION O Inherited blood disorder O an abnormal form of hemoglobin due to a defect through a genetic mutation.
Prevent Disease – Promote Wellness – Improve Quality of Life Michigan update for T Cell Receptor Excision Circle (TREC) analysis for detection of primary.
Novel IL7R Mutation in a T-B+NK+ SCID Infant Y Chang 1, P Sriaroon 2, GA Jervis 1, J Shi 1, MJ Sutcliffe 1, A Petrovic 1, JW Leiding 2 1 All Children’s.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
Patient history 70 year-old male with macrocytic anemia for 10 years, became transfusion dependent. Splenectomy for refractory anemia: 670gm B12, folate,
Human umbilical cord primary cells Human umbilical cord blood mononuclear cells are isolated from umbilical cord blood. Human umbilical cord blood mononuclear.
(Donor T-Cells Transduced with iC9 Suicide Gene)
Clinical, immunological and pathological features of severe combined immunodeficiency (SCID) at PGIMER, Chandigarh Amit Rawat¹, Sagar Bhattad¹, Deepti.
In The Name of God.
with homozygous p.Leu490Pro mutation
Case Western Reserve University and University Hospitals of Cleveland
Relationship between Mixed Chimerism and Clinical Tolerance after Combined Kidney and Hematopoietic Cell Transplantation using Total Lymphoid Irradiation.
Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years  Antonia Kwan, PhD, MRCPCH,
Diagnostic Hematology
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency 
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia  Robert Iannone, James F Casella, Ephraim.
Letermovir(Prevymis™) Guidelines for Inpatient Use
Signaling impairments in maternal T cells engrafted in an infant with a novel IL-2 receptor γ mutation  Aaruni Khanolkar, MBBS, PhD, Jeffrey D. Wilks,
Immunophenotyping of lymphocyte subsets.
Late thymic deficiency after HLA-haploidentical hematopoietic stem cell transplantation for severe combined immunodeficiency  Markus J. Ege, MD, Catharina.
Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency  Amel Hassan,
Mutua C, Karimi. D, Irungu. A, Patil. R, Ngwatu
Primary cellular immunodeficiencies
Dr Ghssemi Ali Associate Professor of Pediatric Hematologist & Oncologist & stem cell transplantation.
Timing for HCT Consultation
Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening  Morna J. Dorsey, MD, MMSc, Christopher C. Dvorak,
Presentation transcript:

University of Wisconsin Newborn Screening for SCID Experience: Spanning the Spectrum Christine Seroogy MD Associate Professor Pediatric Allergy, Immunology & Rheumatology

Initial Presentation SCID infant #1 Birth History: male infant born at 40 wks, via NSVD to parents without consanguinity. Newborn screen drawn on DOL 1 DOL 2- Discharged home DOL 8- PCP contacted by Wisconsin State Lab of Hygiene with abnormal result for SCID screen Drs. Mei Baker and Chuck Brokopp, Wisconsin State Lab of Hygiene

Identified SCID Infant #1: Initial Flow Cytometry FLOW CYTOMETRY abs T cells: 111 ( ) abs CD4 T cells: 56 ( ) abs CD8 T cells: 56 ( ) abs B cells : 28 ( ) abs NK cells: 1112 ( ) %CD45RO (memory T cells): 21 (3-16) %CD45RA (naïve T cells): 12 (77-94) Newborn screen repeated- absent TREC

Initial Management Admitted to AFCH in protective isolation Initiated antimicrobial prophylaxis Initiated intravenous gamma globulin Suspended breastfeeding Continued diagnostic testing for SCID

Diagnostic Testing Utilized Commercial genetic sequencing Research-based genetic sequencing with Dr. Jennifer Puck UCSF Commercial and research-based radiosensitivity testing (Dr. Gatti at UCLA, Drs. Cowan and Yannone UCSF and Lawrence Berkeley National Laboratory) T cell functional studies and FISH for maternal engraftment. ADA testing to Duke University, Dr. Michael Hirschfield

Gene sequencing No deleterious mutations detected in: IL2  R, IL7R  JAK3, CORONIN1A, AK2 CD3 , CD3  ADA DCLRE1C(Artemis) LIGIV RAG1/ RAG 2 Data generated by Dr. Jennifer Puck’s laboratory and GeneDx

Fibroblast analysis Data from the following laboratories: Drs. Richard Gatti, Mort Cowan and Steve Yannone

Identified SCID Infant #1: Persistent T-B-NK+ SCID Phenotype

Challenges in Decision-making for Curative Approach For SCID Timing of transplant—outcome better without pre-existing condition Donor source Conditioning

Transplant Decision High resolution HLA-A,B, C and DR  1 matched cord blood identified. Patient received the following conditioning: Busulfan (maintain css 600 ng/ml): Days -9 to -6 Fludaribine: Days -5 to -2 rATG: Days -4 to -1 GVHD prophylaxis: MMF and CsA Dr. Ken DeSantes, Transplant physician University of Wisconsin

SCID infant #1 has increasing immune cell numbers after HLA- matched umbilical cord blood transplant

Summary of SCID Infant #1 Transplanted on DOL 77, tolerated procedure well. Discharged on DOL 107 and remains clinically stable. Molecular diagnosis is currently unknown. This may represent a novel mutation or a previously unknown presentation of a SCID-associated gene. This case provides evidence that implementation of TREC analysis on newborn screen could identify SCID patients early in order to successfully transplant patients while minimizing morbidity and mortality.

Identified SCID Infant #2: Initial Labs CBC WBC 4.2 HGB 18.1 HCT 54.5 PLT 211 ANC 3108 ( ) ALC 126 ( ) Flow Cytometry Absolute T cells: 3 Absolute B cells: 4 Absolute NK cells: 1 Repeat TREC from peripheral blood: 0 Biochemical testing for ADA confirmed form of SCID

Initial Management Discharged to home with protective isolation Initiated PEG-ADA at 30U/kg twice weekly Initiated antimicrobial prophylaxis Initiated intravenous gamma globulin Continued breastfeeding

Monitoring Therapeutic Effects of PEG-ADA

Identified SCID Infant #2: Improving profound lymphopenia on PEG-ADA

Summary of SCID Infant #2 Infant continues to grow and thrive. Infant remains infection-free. Plan is to proceed to gene therapy at the NIH once infant reaches 10kg.

UW NBS SCID cases: Span the Spectrum Molecularly undefinable SCID T-B-NK+ SCID Isolation in hospital Rapid metabolic test for screening Isolation at home Recombinant enzyme replacement Hematopoietic stem cell transplantation outcome fair Open protocols for gene therapy SCID #1 SCID #2

Present Challenges Duration to follow genetically undefinable forms of SCID to ensure phenotype and move to curative approaches Rapid radiosensitivity test Donor selection and approach to transplant